WO1990000607A3 - Gap gene sequences and diagnostic uses thereof - Google Patents

Gap gene sequences and diagnostic uses thereof Download PDF

Info

Publication number
WO1990000607A3
WO1990000607A3 PCT/US1989/002761 US8902761W WO9000607A3 WO 1990000607 A3 WO1990000607 A3 WO 1990000607A3 US 8902761 W US8902761 W US 8902761W WO 9000607 A3 WO9000607 A3 WO 9000607A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene sequences
gap gene
diagnostic uses
gap
protein
Prior art date
Application number
PCT/US1989/002761
Other languages
French (fr)
Other versions
WO1990000607A2 (en
Inventor
Gail L Wong
Francis P Mccormick
George Martin
Bonnee Rubinfeld
Edward C O'rourke
Robin Clark
Kirston E Koths
Robert F Halenbeck
Mary M Trahey
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/216,888 external-priority patent/US5104975A/en
Application filed by Cetus Corp filed Critical Cetus Corp
Priority to EP89908913A priority Critical patent/EP0466688B1/en
Priority to DE68928242T priority patent/DE68928242T2/en
Publication of WO1990000607A2 publication Critical patent/WO1990000607A2/en
Publication of WO1990000607A3 publication Critical patent/WO1990000607A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C07K14/4706—Guanosine triphosphatase activating protein, GAP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
    • G01N2333/4707—Guanosine triphosphatase activating protein, GAP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Guanosine triphosphatase activating protein (GAP) DNA sequences are described that are useful as cancer diagnostics, particularly to detect cancer cells that express the ras oncogene protein p21 by measuring the level of GAP gene expression or amplification.
PCT/US1989/002761 1988-07-08 1989-06-23 Gap gene sequences and diagnostic uses thereof WO1990000607A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP89908913A EP0466688B1 (en) 1988-07-08 1989-06-23 Gap gene sequences and diagnostic uses thereof
DE68928242T DE68928242T2 (en) 1988-07-08 1989-06-23 GAP GEN SEQUENCES AND DIAGNOSTIC USES THEREOF

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US07/216,888 US5104975A (en) 1988-07-08 1988-07-08 Compositions for detecting ras gene proteins and cancer therapeutics
US216,888 1988-07-08
US23076188A 1988-08-10 1988-08-10
US230,761 1988-08-10
US26080788A 1988-10-21 1988-10-21
US260,807 1988-10-21

Publications (2)

Publication Number Publication Date
WO1990000607A2 WO1990000607A2 (en) 1990-01-25
WO1990000607A3 true WO1990000607A3 (en) 1990-11-01

Family

ID=27396345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/002761 WO1990000607A2 (en) 1988-07-08 1989-06-23 Gap gene sequences and diagnostic uses thereof

Country Status (7)

Country Link
EP (2) EP0649908A1 (en)
AT (1) ATE156518T1 (en)
AU (1) AU627764B2 (en)
CA (1) CA1339357C (en)
DE (1) DE68928242T2 (en)
IL (1) IL90780A0 (en)
WO (1) WO1990000607A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9468495B2 (en) 2005-06-20 2016-10-18 Medtronic Ablation Frontiers Llc Ablation catheter

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763573A (en) * 1988-08-10 1998-06-09 Chiron Corporation GTPase activating protein fragments
US5830684A (en) * 1988-08-10 1998-11-03 Chiron Corporation Native type II GAP, methods for purifying various GAPs and uses of GAPs to diagnose cancer
AU652724B2 (en) * 1989-08-21 1994-09-08 Chiron Corporation Peptides from GTPase-activating protein (GAP) and diagnostic and therapeutic use thereof
EP0537155A1 (en) * 1990-03-30 1993-04-21 Chiron Corporation PURIFIED RAP GAPs, RAP GAP SEQUENCES, AND USES THEREOF
FR2694296B1 (en) * 1992-07-30 1994-09-02 Rhone Poulenc Rorer Sa Peptides inhibiting the activity of ras proteins, preparation and use.
US6238881B1 (en) 1996-11-06 2001-05-29 Onyx Pharmaceuticals, Inc. Nucleic acids and polypeptides related to a guanine exchange factor of Rho GTPase
JP2002530109A (en) * 1998-11-23 2002-09-17 インサイト・ファーマスーティカルズ・インコーポレイテッド GTPase-related protein
AU2003298735A1 (en) 2002-11-25 2004-06-18 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
US20220348900A1 (en) * 2019-08-14 2022-11-03 Modernatx, Inc. Processes for purifying downstream products of in vitro transcription

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Biochemical and Biophysical Research Communications, Volume 159, No. 3, 31 March 1989, Academic Press, Inc., (Duluth, Mn, US), T. UEDA et al.: "GTPase Activating Proteins from the Smg-21 GTP-Binding Protein Having the Same Effector Domain as the Ras Proteins in Human Platelets", pages 1411-1419 *
Cancer Research, Volume 49, 15 March 1989, (Philadelphia, PA, US), C. DUANMU et al.: "Tubilin-Dependent Hydrolysis of Guanosine Triphosphate as a Screening Test to Identify New Antitubulin Compounds with Potential as Antimitotic Agents: Application to Carbamates of Aromatic Amines", pages 1344-1348 *
Nature, Volume 332, 7 April 1988, (London, GB), C. CALES et al.: "The Cytoplasmic Protein GAP is Implicated as the Target for Regulation by the ras Gene Product", pages 548-551 *
Nature, Volume 335, 1 September 1988, (London, GB), U.S. VOGEL et al.: "Cloning of Bovine GAP and its Interaction with Oncogenic Ras p21", pages 90-93 *
Science, Volume 238, 23 Oktober 1987, (Washington, DC, US), M. TRAHEY et al.: "A Cytoplasmic Protein Stimulates Normal N-Ras P21 GRPase, but does not affect Oncogenic Mutants", pages 542-545 *
Science, Volume 240, 22 April 1988, (Washington, DC, US), H. ADARI et al9: "Guanosine Triphosphatase Activating Protein (GAP) Interacts with the P21 Ras Effector Binding Domain", pages 518-521 *
Science, Volume 242, 23 December 1988, (Washington, DC, US), M. TRAHEY et al.: "Molecular Cloning of two types of GAP Complementary DNA from Human Placenta", pages 1697-1700 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9468495B2 (en) 2005-06-20 2016-10-18 Medtronic Ablation Frontiers Llc Ablation catheter

Also Published As

Publication number Publication date
ATE156518T1 (en) 1997-08-15
DE68928242T2 (en) 1997-12-18
AU4034989A (en) 1990-02-05
AU627764B2 (en) 1992-09-03
DE68928242D1 (en) 1997-09-11
WO1990000607A2 (en) 1990-01-25
CA1339357C (en) 1997-08-26
EP0466688A1 (en) 1992-01-22
EP0466688B1 (en) 1997-08-06
EP0649908A1 (en) 1995-04-26
IL90780A0 (en) 1990-01-18

Similar Documents

Publication Publication Date Title
ATE130873T1 (en) PROOF OF EXPRESSION OF NEW GENES AND PRODUCTS.
ES8609472A1 (en) Use of non-hybridizable nucleic acids for the detection of nucleic acid hybridization
ES8700324A1 (en) Modified labeled nucleotides and polynucleotides and methods of preparing, utilizing and detecting same.
HK1000786A1 (en) Dna constructs for endogenous gene activation and expression modification.
AU7222698A (en) Method of preparing a standard diagnostic gene transcript pattern
ES2059361T3 (en) RECOMBINANT PROTEIN COMPLEX THAT HAS FACTOR VIII: C ACTIVITY, ITS PRODUCTION AND USE.
AU560340B2 (en) Rennin from recombinant dna
CA2002868A1 (en) Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE69840107D1 (en) glucose biosensor
AU6589094A (en) 7-deazapurine modified oligonucleotides
EP0357611A4 (en) A method of detection of carcinogenic human papillomavirus
NO904633D0 (en) AMPLIFICATION OF NUCLEIC ACIDS BY TRANSCRIPABLE HAIRNEL PROBE.
DE69503129D1 (en) PTERIDINE NUCLEOTIDE DERIVATIVES AS FLUORESCENT PROBE
ES8702431A1 (en) Blood coagulation inhibiting proteins, process for preparing them and their use.
EP0247730A3 (en) Antibodies, their preparation and use and products containing them
ATE269402T1 (en) IKK-BETA PROTEINS, NUCLEIC ACIDS AND METHODS
AU3975078A (en) PROCESS AND REAGENT FOR Thr. DETERMINATION OF o C AMYLASE
WO1990000607A3 (en) Gap gene sequences and diagnostic uses thereof
AU3025597A (en) Method of providing novel dna sequences
OA09116A (en) Novel protein, sequences containing the gene therefore vectors, methods of preparation and use.
ATE70280T1 (en) CHARACTERISTIC POLYPEPTIDES AND ANTIBODIES OF PAPILLOMAVIRUS, DIAGNOSTIC METHODS AND VACCINATIONS USING THE SAME.
AU6745287A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
EP0306219A3 (en) Novel hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
EP0293079A3 (en) Chlamydia vaccine
NL185574C (en) PROCESS FOR THE MICROBIOLOGICAL PREPARATION OF 17-HYDROXYANDROSTA-1,4-DIE-3-ON AND ANDROSTA-1,4-DIE-3,17-DION.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BG DK FI HU JP NO

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BG DK FI HU JP NO

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989908913

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989908913

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1989908913

Country of ref document: EP